Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients

Longitudinal Dynamics of Angiotensin II Type 1 Receptor Antibodies Around Kidney Transplantation and Their Impact on Clinical Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07374484

Acronym

AT1R

Enrollment

241

Registered

2026-01-28

Start date

2024-12-10

Completion date

2025-12-09

Last updated

2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiotensin II Type 1 Receptor Antibody, Graft Survival, Kidney Transplantation

Keywords

Angiotensin II Type 1 Receptor Antibody, Kidney Transplantation, Graft Survival

Brief summary

This study aims to investigate the dynamics of Angiotensin II Type 1 Receptor Antibodies (AT1R-Ab) before and after kidney transplantation. The purpose is to understand how changes in AT1R-Ab levels may impact post-transplant kidney function and graft survival. Participants will include kidney transplant recipients, and their AT1R-Ab levels will be monitored over a one-year period. This research may help develop better predictive models for transplant outcomes, improving clinical decision-making for transplant physicians.

Detailed description

The study will be conducted as a prospective cohort study involving kidney transplant recipients. The participants will undergo monitoring of their AT1R-Ab levels at multiple time points before and after the transplantation, including 2 weeks, 3 months, and 1 year post-transplant. Data collected will include clinical information such as kidney function tests, graft survival rates, and post-transplant complications. The study will aim to correlate AT1R-Ab dynamics with clinical outcomes such as delayed graft function (DGF), graft loss, and creatinine levels.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

Eligible patients were those who had serum samples collected at pre-transplant and at 2 weeks, 3 months, and 1-year post-transplant, with a minimum follow-up of 1 year

Design outcomes

Primary

Measure	Time frame	Description
Biopsy-Proven Acute Rejection (BPAR) within 3 years post-transplant	Up to 3 years post-transplant	This study evaluates biopsy-proven acute rejection (BPAR) as the primary outcome, using protocol biopsies at 2 weeks and 1 year post-transplant.

Secondary

Measure	Time frame	Description
Renal Function: Serum Creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant	At 2 weeks, 3 months, and 1 year post-transplant	Secondary outcomes will include renal function, assessed by serum creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant. The relationship between AT1R-Ab levels and renal function will be analyzed.

Countries

South Korea

Outcome results